Anti-CXorf21 antibody (ab69152)
- Datasheet
- References
- Protocols
Overview
-
Product name
Anti-CXorf21 antibody -
Description
Mouse polyclonal to CXorf21 -
Host species
Mouse -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Full length human CXorf21 protein (NP_079435)
-
Positive control
- CXorf21 transfected 293T cell lysate.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.20
Constituents: Whole serum, 8% Sodium chloride, 0.2% Potassium chloride, 91% dH2O, 0.2% Monobasic dihydrogen potassium phosphate, 0.6% Dibasic monohydrogen sodium phosphate, 2.68% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab69152 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | 1/500 - 1/1000. Detects a band of approximately 34 kDa (predicted molecular weight: 34 kDa). |
Target
-
Relevance
The function of CXorf21 is unknown. -
Database links
- Entrez Gene: 80231 Human
- SwissProt: Q9HAI6 Human
-
Alternative names
- Chromosome X open reading frame 21 antibody
- FLJ11577 antibody
- Hypothetical protein LOC80231 antibody
- Uncharacterized protein CXorf21 antibody
Images
-
All lanes : Anti-CXorf21 antibody (ab69152) at 1/500 dilution
Lane 1 : CXorf21 transfected 293T cell lysate
Lane 2 : Non-transfected 293T cell lysate
Lysates/proteins at 25 µg per lane.
Secondary
All lanes : Goat Anti-Mouse IgG (H&L)-HRP Conjugate at 1/2500 dilution
Predicted band size: 34 kDa
Observed band size: 34 kDa
Protocols
Datasheets and documents
References
ab69152 has not yet been referenced specifically in any publications.